Roche: further positive data in type 1 SMA

(CercleFinance.com) - Roche has announced new positive two-year data from part 2 of FIREFISH, a global phase 2/3 study evaluating Evrysdi in infants enrolled at one to seven months of age with symptomatic type 1 spinal muscular atrophy (SMA).


The data showed that Evrysdi continued to improve motor function between months 12 and 24, including the ability to sit without support, as well as survival, improving the ability to eat and reduce the need for continuous ventilation.

The data also suggests that Evrysdi continued to improve the child's ability to swallow and reduce hospitalisations compared to the natural course of type 1 SMA. The safety of Evrysdi was consistent with its established profile.


Copyright (c) 2021 CercleFinance.com. All rights reserved.